Skip to main content
NTLA
NASDAQ Life Sciences

Intellia Secures $400M Non-Dilutive Debt Facility with OrbiMed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$12.75
Mkt Cap
$1.785B
52W Low
$7.95
52W High
$28.25
52W Position info
60% above low
Off High info
55% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

NTLA sits 60% above its 52-week low of $7.95.

Summary

Intellia closed a $400M non-dilutive senior secured term loan with OrbiMed, drawing $75M upfront with the rest tied to lonvo-z milestones. The facility is secured by substantially all assets including IP and carries restrictive covenants.


Key Events · Financing and Capital Events · NTLA

  • $400M Credit Facility Closed

    Intellia entered a five-year senior secured credit facility with OrbiMed for up to $400M, with $75M drawn at closing on September 4, 2026.

  • Milestone-Based Tranche Structure

    Additional draws include $75M upon FDA approval of lonvo-z BLA, three $40M draws tied to revenue targets, $30M tied to an equity raise, and an uncommitted $100M incremental facility.

  • Interest and Maturity Terms

    Loans bear interest at the greater of 3.00% or one-month SOFR plus 6.15% margin, payable monthly, maturing September 4, 2031.

  • Security and Covenants

    Obligations are secured by a first-priority lien on substantially all assets including intellectual property. Covenants require maintaining at least $50M in controlled accounts until FDA approval of lonvo-z BLA.


Analysis · NTLA · Life Sciences

Intellia closed a $400 million senior secured credit facility with OrbiMed, drawing $75 million upfront. The remaining $325 million is tied to milestones including FDA approval of lonvo-z, revenue targets, and an equity raise. This non-dilutive financing extends Intellia's cash runway without issuing shares, but comes with a first-priority lien on substantially all assets including intellectual property, restrictive covenants, and a liquidity floor of $50 million until BLA approval. The interest rate of SOFR + 6.15% (floor 9.15%) reflects the risk profile of a pre-commercial biotech.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NTLA was trading at $12.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $7.95 to $28.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NTLA - Latest Insights

NTLA
Nov 12, 2026, 4:14 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.60
Real-time Price: $10.01 info
Change: -$0.595 (-6%) info
Market Cap: $1.414B info
NTLA
Nov 12, 2026, 10:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $10.72
Real-time Price: $10.01 info
Change: -$0.715 (-7%) info
Market Cap: $1.414B info
NTLA
Nov 05, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $12.30
Real-time Price: $10.01 info
Change: -$2.30 (-19%) info
Market Cap: $1.414B info
NTLA
Sep 08, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $12.74
Real-time Price: $10.01 info
Change: -$2.73 (-21%) info
Market Cap: $1.414B info
NTLA
Sep 08, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $13.69
Real-time Price: $10.01 info
Change: -$3.68 (-27%) info
Market Cap: $1.414B info